Cogent Biosciences (Cogent Biosciences) Total Current Assets : $270.77 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cogent Biosciences Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Cogent Biosciences's total current assets for the quarter that ended in Dec. 2023 was $270.77 Mil.

Cogent Biosciences Total Current Assets Historical Data

The historical data trend for Cogent Biosciences's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogent Biosciences Total Current Assets Chart

Cogent Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

40.59

244.91

222.63

264.97

270.77

Cogent Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															264.97	226.27	334.52	285.95	270.77

Cogent Biosciences Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Cogent Biosciences's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	265.71	+	0	+	0	+	5.061
	=	270.77

Cogent Biosciences's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	265.71	+	0	+	0	+	5.061
	=	270.77

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Cogent Biosciences (NAS:COGT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Cogent Biosciences's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	265.71	-	55.635	+	0.75 * 0	+	0.5 * 0
=	210.08

Cogent Biosciences Total Current Assets Related Terms

Thank you for viewing the detailed overview of Cogent Biosciences's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cogent Biosciences (Cogent Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cogent Biosciences Inc (NAS:COGT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451

Website

https://www.cogentbio.com

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Executives

Fairmount Funds Management Llc	10 percent owner, other: See Remarks	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Evan Kearns	officer: Chief Legal Officer	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
John L. Green	officer: Chief Financial Officer	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
John Edward Robinson	officer: Chief Scientific Officer	C/O COGENT BIOSCIENCES, INC., 200 CAMBRIDGE PARK DRIVE, SUITE 2500, CAMBRIDGE MA 02140
Christopher W. Cain	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Peter Evan Harwin	director	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Todd Shegog	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Jessica Sachs	officer: Chief Medical Officer	C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Matthew Ros	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Andrew R Robbins	director, officer: President and CEO	C/O 3200 WALNUT ST, BOULDER CO 80301
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018